Women with newly diagnosed ovarian cancer and a BRCA mutation see sustained benefits in progression free survival rates after two years of maintenance olaparib therapy, a clinical trial analysis suggests.
Reuters Health Information
Maintenance Olaparib Benefits Sustained Beyond 2 Years Treatment
